Short Interest in Orion Oyj (OTCMKTS:ORINY) Expands By 25.0%

Orion Oyj (OTCMKTS:ORINY) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 500 shares, a growth of 25.0% from the October 31st total of 400 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 5.0 days.

Orion Oyj Price Performance

Shares of OTCMKTS ORINY opened at $23.40 on Monday. Orion Oyj has a 1 year low of $17.50 and a 1 year high of $28.55. The stock has a market capitalization of $6.61 billion, a P/E ratio of 18.57 and a beta of 0.22. The company’s 50-day moving average is $25.32 and its 200 day moving average is $23.76. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.39 and a quick ratio of 1.29.

Orion Oyj (OTCMKTS:ORINY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.63 earnings per share for the quarter. Orion Oyj had a return on equity of 41.41% and a net margin of 23.01%. The company had revenue of $517.97 million for the quarter. On average, sell-side analysts expect that Orion Oyj will post 1.26 earnings per share for the current year.

Orion Oyj Cuts Dividend

The firm also recently announced a dividend, which was paid on Thursday, November 7th. Stockholders of record on Wednesday, October 16th were issued a dividend of $0.2405 per share. The ex-dividend date was Wednesday, October 16th. Orion Oyj’s payout ratio is 26.98%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.